

Financial events: agenda 2012

Event	Date * **
Q4 Full Year Sales 2011	25 January 2012
Annual Accounts 2011	7 March 2012
Q1 Sales 2012	2 May 2012
Q2 Sales 2012	25 July 2012
Half Year Results 2012	31 August 2012
Q3 Sales 2012	6 November 2012

Financial year ended 31 December

Subject to modification** Press releases are distributed after the financial markets closure*

About STENTYS:

Based in Princeton, N.J., and Paris, Stentys has developed a new generation of stents to treat acute myocardial infarction (AMI). Founded by Jacques Séguin, M.D., Ph.D., and Gonzague Issenmann, Stentys received the CE mark for its flagship products in 2010. Its self-apposing stents adapt to the anatomic changes of the arteries in the post-infarction phase and thus prevent the malapposition problems associated with conventional stents. Stentys has commenced its marketing activities in several European countries.

More information on www.stentys.com.

Contacts:

Stentys

Stanislas Piot

CFO

Tel.: +33 (0)1 44 53 99 42

stan.p@stentys.com

NewCap.

Investor relations & Financial Communications

Axelle Vuillermet / Pierre Laurent

Tel.: +33 (0)1 44 71 94 94

stentys@newcap.fr

STENTYS is listed on NYSE Euronext Paris

ISIN : FR0010949404 – STNT